OFIX Orthofix Medical Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 884624 · Fiscal year ends 12/23
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY2.1%
TTM net income YoY62.2%
TTM EPS YoY63.7%
Revenue 3-yr CAGR7.7%
Net income 3-yr CAGR—
Margins
Gross margin70.9%
Operating margin-2.5%
Net margin-5.4%
FCF margin-5.3%
EBITDA margin3.9%
Returns
ROE-10.3%
ROA-5.3%
ROIC (approx.)-2.9%
Asset turnover0.99x
Leverage & solvency
Liabilities / assets49.8%
Debt / equity0.52x
Current ratio3.11x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.09x
Accruals ratio-5.8%
Payout ratio—
Capex / revenue5.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $822.31M | $799.49M | $746.64M | $460.71M | $464.48M |
| Cost of revenue | $256.30M | $253.61M | $260.37M | $123.54M | $114.91M |
| Gross profit | $566.02M | $545.88M | $486.27M | $337.17M | $349.56M |
| R&D expense | $65.85M | $73.64M | $80.23M | $49.06M | $49.62M |
| SG&A expense | $554.33M | $532.52M | $530.39M | $308.78M | $69.35M |
| Operating income | -$81.43M | -$84.62M | -$139.11M | -$13.27M | -$8.31M |
| Pretax income | -$90.81M | -$123.88M | -$148.68M | -$17.71M | -$13.49M |
| Income tax | $1.38M | $2.12M | $2.72M | $2.04M | $24.88M |
| Net income | -$92.19M | -$126.00M | -$151.40M | -$19.75M | -$38.38M |
| EBITDA | -$4.11M | -$24.56M | -$86.05M | $15.75M | $21.28M |
| EPS (basic) | -2.33 | -3.30 | -4.12 | -0.98 | -1.95 |
| EPS (diluted) | -2.33 | -3.30 | -4.12 | -0.98 | -1.95 |
| Weighted avg. shares (diluted) | 39.60M | 38.13M | 36.73M | 20.05M | 19.69M |
| Banking | |||||
| Net interest income | -$17.49M | -$29.63M | -$8.63M | -$1.29M | -$1.84M |
| Provision for credit losses | $2.25M | $2.00M | $820,000 | $2.10M | $444,000 |
| Balance sheet | |||||
| Cash & equivalents | $82.03M | $83.24M | $33.11M | $50.70M | $87.85M |
| Receivables | $135.75M | $134.71M | $128.10M | $82.86M | $78.56M |
| Inventory | $172.32M | $189.45M | $222.17M | $100.15M | $82.97M |
| Current assets | $416.85M | $433.29M | $420.44M | $255.99M | $269.52M |
| PP&E, net | $129.40M | $139.80M | $159.06M | $58.23M | $59.25M |
| Goodwill | $194.93M | $194.93M | $194.93M | $71.32M | $71.32M |
| Intangibles | $72.77M | $98.80M | $117.49M | $47.39M | $52.67M |
| Total assets | $850.65M | $893.29M | $925.32M | $458.63M | $476.62M |
| Current liabilities | $170.48M | $168.63M | $165.22M | $83.62M | $105.83M |
| Short-term debt | $0 | $0 | $1.25M | — | — |
| Long-term debt | $157.39M | $157.01M | $93.11M | — | — |
| Total debt | $157.39M | $157.01M | $94.36M | — | — |
| Total liabilities | $400.61M | $390.17M | $326.58M | $121.77M | $139.69M |
| Shareholders' equity | $450.04M | $503.12M | $598.73M | $336.86M | $336.93M |
| Net debt | $75.37M | $73.78M | $61.25M | — | — |
| Shares outstanding | 39.83M | 38.49M | 37.16M | 20.16M | 19.84M |
| Cash flow statement | |||||
| Operating cash flow | $33.35M | $25.79M | -$45.75M | -$11.54M | $18.48M |
| Capital expenditure | $34.63M | $34.88M | $62.05M | $23.16M | $17.79M |
| Free cash flow | -$1.28M | -$9.09M | -$107.80M | -$34.70M | $690,000 |
| Investing cash flow | -$34.60M | -$27.58M | -$33.13M | -$24.53M | -$23.01M |
| Financing cash flow | -$786,000 | $50.71M | $65.32M | -$78,000 | -$3.62M |
| Depreciation & amortization | $77.32M | $60.06M | $53.06M | $29.02M | $29.60M |
| Stock-based compensation | $28.69M | $32.45M | $35.71M | $18.44M | $15.43M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.